Neil Sun Chua

机构：University of Alberta, Cross Cancer Institute · ORCID：0000-0002-0093-7480

发表论文 99 篇 · 总被引 7126 次 · h-index 30

代表论文

• Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019 · The Lancet · 被引 3351)
• Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma (2017 · Journal of Clinical Oncology · 被引 428)
• Structured Exercise after Adjuvant Chemotherapy for Colon Cancer (2025 · New England Journal of Medicine · 被引 344)
• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial (2024 · The Lancet Oncology · 被引 245)
• Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study (2018 · Journal of Clinical Oncology · 被引 171)
• Prevalence and prognostic significance of malnutrition in patients with cancers of the head and neck (2019 · Clinical Nutrition · 被引 88)